Registration for 2020 Germline schemes closes in:

New paper published on EQA for circulating tumour DNA testing

1 year ago


Molecular analysis of circulating tumour DNA (ctDNA) is becoming increasingly important in clinical treatment decisions. A pilot External Quality Assessment (EQA) scheme for ctDNA analysis was organized by four European EQA providers under the umbrella organization IQN Path, in order to investigate the feasibility of delivering an EQA to assess the detection of clinically relevant variants in plasma circulating cell-free DNA (cfDNA) and to analyze reporting formats.


Thirty-two experienced laboratories received 5 samples for EGFR mutation analysis and/or 5 samples for KRAS and NRAS mutation analysis. Samples were artificially manufactured to contain 3 mL of human plasma with 20 ng/mL of fragmented ctDNA and variants at allelic frequencies of 1 and 5%.


The scheme error rate was 20.1%. Higher error rates were observed for RAS testing when compared to EGFR analysis, for allelic frequencies of 1% compared to 5%, and for cases including 2 different variants. The reports overinterpreted wild-type results and frequently failed to comment on the amount of cfDNA extracted.


The pilot scheme demonstrated the feasibility of delivering a ctDNA EQA scheme and the need for such a scheme due to high error rates in detecting low frequency clinically relevant variants. Recommendations to improve
reporting of cfDNA are provided.

Keywords: KRAS, NRAS, EGFR, Mutation testing, ctDNA, cfDNA, Lung cancer, Colorectal cancer

Download a copy by clicking on the image below:

Next: Calling all our members - do you want to join our NGS scheme advisory group?
Translate »